SBIR/STTR Research Award

THE PROPOSED SBIR PROJECT IS DESIGNED TO DEVELOP AN ASSAY WHICH WILL ALLOW THE DIRECT MEASUREMENT OF A COMMON CARCINOGEN BOUND TO DNA (DNA-ADDUCT) AND ESTABLISH THE CORRELATION BETWEEN THE BURDEN OF THIS ADDUCT AND THE INDUSTRIAL EXPOSURE TO THE

Award identifier e6c6f1b5319b5d189f5dae88317f12f59c243c989638cd3ade00ea42c5645f7bAwarding agency Department of Health and Human Services

Award amount

$48,911

Program and phase

SBIR · Phase I

Award year

1983

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Vestar, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE PROPOSED SBIR PROJECT IS DESIGNED TO DEVELOP AN ASSAY WHICH WILL ALLOW THE DIRECT MEASUREMENT OF A COMMON CARCINOGEN BOUND TO DNA (DNA-ADDUCT) AND ESTABLISH THE CORRELATION BETWEEN THE BURDEN OF THIS ADDUCT AND THE INDUSTRIAL EXPOSURE TO THE CARCINOGEN. THE PROJECT WILL BE PERFORMED IN THREE PHASES: ASSAY DEVELOPMENT; ASSAY OPTIMIZATION, AND CORRELATION OF ADDUCT BURDEN WITH EXPOSUREINDEX; COMMERCIALIZATION. THE THIRD PHASE WILL BE FUNDED BYA COMMERCIAL PARTNER. COMMERCIALIZATION WILL ENTAIL A SERVICE WHICH MEASURES THE DNA-ADDUCT BURDEN IN INDIVIDUALS.THE OBJECTIVE OF THIS PHASE I RESEARCH IS TO DEVELOP AND DEMONSTRATE AN ASSAY SYSTEM THAT IS CAPABLE OF MEASURING IN HUMANS THE DNA ADDUCTS OF THE PREVALENT CHEMICAL CARCINOGEN,BENZO(A)PYRENE (B(A)P). B(A)P BECOMES MUTAGENIC AND CARCINOGENIC AFTER METABOLIC ACTIVATION. THE COVALENT BINDING OF THE ACTIVATED METABOLITE TO CELLULAR DNA IS CONSIDERED TO BE AN IMPORTANT STEP IN THE INITIATION OF MALIGNANT TRANSFORMATION. IF THESE COVALENT ADDUCTS TO DNA CAN BE DIRECTLY MONITORED IN PEOPLE AT RISK TO CARCINOGEN EXPOSURE, ACTIONS CAN BE TAKEN TO PREVENT FURTHEREXPOSURE AND POSSIBLY AVOID THE INDUCTION OF CANCER AT A OF BIFUNCTIONAL REAGENTS (EDTA-PH-B[OH]2) CONTAINING A POWERFUL METAL CHELATING EDTA MOIETY LINKED TO GROUP THAT REACTS WITH THE CIS-8, 9-DIHYDRODIOL PORTION OF THE GUANOSINE ADDUCT (BPDE-DG) OF A B(A)P METABOLITE. BLOOD (10 ML) IS DRAWN FROM B(A)P EXPOSED HUMANS, LYMPHOCYTES ARE SEPARATED, AND DNA IS EXTRACTED AND ENZYMATICALLY HYDROLYSEDTO NUCLEOSIDES BY CONVENTIONAL METHODS. THE EDTA-PH-B(OH)2 IS COMPLEXED WITH A SHORT-LIVED METAL ISOTOPE (E.G.(111)IN, (99)TC) AND THEN CONDENSED WITH THE BPDE-DG TO FORM A CYCLICBORONATE ESTER. THE STABLE COMPLEX OF THE RADIOACTIVE METALEDTA-PH(OH)2 - BPDE-DG IS CHROMATOGRAPHICALLY SEPARATED FROMOTHER IMPURITIES AND DETECTED. WITH A DETECTABILITY CRITERION OF 100 DPM, 5 X 10(4) MOLECULES OF THE DNA ADDUCT CAN BE DETECTED IF (99)TC IS USED. THE GOAL OF THE PHASE I RESEARCH IS TO ATTAIN A DETECTABILITY LEVEL OF 10(7) MOLECULES SO THAT ONE B(A)P ADDUCT CAN BE DETECTED PER CELL FROM 10 ML OF BLOOD. WHEN THE CHEMICAL ASSAY IS DEMONSTRATED "IN VITRO", IT WILL BE USED TO MEASURE THE ADDUCTS IN BLOOD SAMPLES DRAWN FROM TWO COKE OVEN WORKERS. EPIDEMIOLOGY STUDIES CORRELATING THE ADDUCT BURDEN WITH CUMULATION OCCUPATION DOSE WILL BE CONDUCTED IN PHASE II.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.